Gratus Capital LLC Abb Vie Inc. Transaction History

Gratus Capital LLC

$2.39 Billion
Q2 2024

A detailed history of Gratus Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Gratus Capital LLC holds 13,912 shares of ABBV stock, worth $2.83 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

13,912

Previous 12,622 10.22%

Holding current value

$2.83 Million

Previous $2.3 Million 3.83%

% of portfolio

0.1%

Previous 0.11%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$154.79 - $180.76 $199,679 - $233,180	1,290 Added 10.22%	13,912 $2.39 Million
Q1 2024 May 13, 2024	BUY	$159.82 - $182.1 $228,063 - $259,856	1,427 Added 12.75%	12,622 $2.3 Million
Q4 2023 Feb 07, 2024	BUY	$137.6 - $154.97 $783,769 - $882,709	5,696 Added 103.58%	11,195 $1.73 Million
Q3 2023 Oct 26, 2023	SELL	$133.59 - $154.65 $374,319 - $433,329	-2,802 Reduced 33.75%	5,499 $819,000
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $14.2 Million - $17.7 Million	-107,370 Reduced 92.82%	8,301 $1.12 Million
Q1 2023 Apr 19, 2023	SELL	$144.61 - $166.54 $521,608 - $600,709	-3,607 Reduced 3.02%	115,671 $18.4 Million
Q4 2022 Jan 27, 2023	SELL	$138.31 - $165.87 $4.62 Million - $5.54 Million	-33,376 Reduced 21.86%	119,278 $0
Q3 2022 Nov 03, 2022	BUY	$134.21 - $153.93 $2.28 Million - $2.62 Million	17,017 Added 12.55%	152,654 $20.5 Million
Q2 2022 Jul 29, 2022	BUY	$137.62 - $174.96 $1.31 Million - $1.66 Million	9,512 Added 7.54%	135,637 $20.8 Million
Q1 2022 Apr 29, 2022	BUY	$131.98 - $163.75 $746,214 - $925,842	5,654 Added 4.69%	126,125 $20.4 Million
Q4 2021 Jan 31, 2022	BUY	$107.43 - $135.93 $525,225 - $664,561	4,889 Added 4.23%	120,471 $16.3 Million
Q3 2021 Nov 05, 2021	BUY	$106.4 - $120.78 $1.88 Million - $2.13 Million	17,667 Added 18.04%	115,582 $12.5 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $1.04 Million - $1.15 Million	9,851 Added 11.19%	97,915 $11 Million
Q1 2021 May 04, 2021	BUY	$102.3 - $112.62 $980,136 - $1.08 Million	9,581 Added 12.21%	88,064 $9.53 Million
Q4 2020 Feb 03, 2021	BUY	$80.49 - $108.67 $280,507 - $378,714	3,485 Added 4.65%	78,483 $8.41 Million
Q3 2020 Oct 30, 2020	SELL	$85.91 - $100.83 $378,004 - $443,652	-4,400 Reduced 5.54%	74,998 $6.57 Million
Q2 2020 Aug 11, 2020	SELL	$73.37 - $98.18 $1.35 Million - $1.81 Million	-18,442 Reduced 18.85%	79,398 $7.8 Million
Q1 2020 May 01, 2020	BUY	$64.5 - $97.79 $640,549 - $971,152	9,931 Added 11.3%	97,840 $7.45 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $93,408 - $116,873	1,295 Added 1.5%	87,909 $7.78 Million
Q3 2019 Oct 30, 2019	BUY	$62.98 - $75.72 $361,001 - $434,027	5,732 Added 7.09%	86,614 $6.56 Million
Q2 2019 Aug 07, 2019	BUY	$65.7 - $83.98 $1.5 Million - $1.92 Million	22,877 Added 39.44%	80,882 $5.88 Million
Q1 2019 May 14, 2019	SELL	$77.14 - $90.79 $2.1 Million - $2.48 Million	-27,262 Reduced 31.97%	58,005 $4.68 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $48 Million - $59.1 Million	-615,980 Reduced 87.84%	85,267 $7.86 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $47.9 Million - $59.1 Million	615,855 Added 721.21%	701,247 $8.56 Million
Q3 2018 Nov 09, 2018	BUY	$88.91 - $98.84 $239,256 - $265,978	2,691 Added 3.25%	85,392 $8.08 Million
Q2 2018 Aug 13, 2018	BUY	$89.78 - $106.23 $195,540 - $231,368	2,178 Added 2.7%	82,701 $7.66 Million
Q1 2018 May 10, 2018	SELL	$92.01 - $123.21 $1.07 Million - $1.43 Million	-11,602 Reduced 12.59%	80,523 $7.62 Million
Q4 2017 Feb 07, 2018	BUY	$89.56 - $98.21 $905,362 - $992,804	10,109 Added 12.33%	92,125 $8.91 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $439,915 - $561,907	6,298 Added 8.32%	82,016 $7.29 Million
Q2 2017 Aug 08, 2017	BUY	N/A	75,718	75,718 $5.49 Million

Others Institutions Holding ABBV

# of Institutions

3,771

Shares Held

1.28B

Call Options Held

13M

Put Options Held

9.83M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $360B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gratus Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gratus Capital LLC with notifications on news.

Account

Gratus Capital LLC Abb Vie Inc. Transaction History